Concurrent radiation therapy and lenalidomide in myeloma patient

Radiotherapy and Oncology

Volumn 87, Issue 1, 2008, Pages 152-153

  Marchand, Virginie ^a   Decaudin, Didier ^a   Servois, Vincent ^a   Kirova, Youlia M ^a  

^a INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; THALIDOMIDE; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; ADULT; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CASE REPORT; DRUG MEGADOSE; DRUG WITHDRAWAL; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; LETTER; MALE; MULTIPLE MYELOMA; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DEXAMETHASONE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; THALIDOMIDE;

EID: 41849085548     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2007.11.018     Document Type: Letter

References (4)

1. Richardson P.G., Schlossman R., Hideshima T., et al. New treatments for multiple myeloma. Oncology (Williston Park) 19 (2005) 1781-1792
2. Richardson P.G., Mitsiades C., Schlossman R., et al. New drugs for myeloma. Oncologist 12 (2007) 664-689
3. Rao K.V. Lenalidomide in the treatment of multiple myeloma. Am J Health Syst Pharm 64 (2007) 1799-1807
4. Common Terminology Criteria for Adverce Events v 3.0 (CTCAE), published Aug 9, 2006.